BALDO LANCE 4
4 · Adaptive Biotechnologies Corp · Filed Apr 16, 2021
Insider Transaction Report
Form 4
BALDO LANCE
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-04-14$7.80/sh+2,000$15,600→ 24,894 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-04-14−2,000→ 339,250 totalExercise: $7.80Exp: 2029-05-06→ Common Stock (2,000 underlying) - Sale
Common Stock
2021-04-14$44.50/sh−2,000$89,000→ 22,894 total
Footnotes (2)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020 and modified on March 3, 2021.
- [F2]The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested.